Search results for: Simon Brassel
Filter search results
Simon Brassel
4 March 2019
Simon is a Health Economist and Electrical Engineer with over ten years of professional experience in international healthcare markets. His expertise covers the whole spectrum of health technologies, from pharmaceuticals…
The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision
8 October 2020
…they need to be. The time for multi-stakeholder action to recognise and reward the broader value of vaccines and other healthcare interventions is now (Brassel et al. 2020a; Brassel et…
OHE at ISPOR Europe 2023
13 November 2023, 12:00am
…Simon Brassel Poster Session Time: 15:30 – 18:30 Discussion Period: 16:00 – 17:00 Poster Session Issues Regarding Pricing and Access to Gene and Advanced Therapy Medicinal Products Lotte Steuten (panelist)…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…key to efficient pricing and use of cancer medicines. The Research Paper outlines some for addressing these shortcomings. A new OHE Research Paper by Simon Brassel, Olga Rozanova, and Adrian…
Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
16 January 2024
…appropriate for estimating the required magnitude of the global pull incentive (Brassel et al., 2023). The estimates are based on a review of cost and success estimates for antibiotics and are…
Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?
4 August 2020
…on investment (ROI) per £1 spent on various vaccination programmes from the perspective of the UK government (Brassel and Steuten, 2020). The results show that vaccine programmes generally provide positive…
Biosimilars’ Price Dynamic in Europe
30 June 2010
…with biosimilars. Source: Simon Kucher and Partners (click graphic to enlarge) Dr Matthias Liefner is a Director in the Life Sciences Division at Simon Kucher and Partners. Publication now…
Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?
17 September 2020
…gained or the health opportunity costs of vaccination programs that were previously shown cost-effective to the NHS. Brassel, S., Neri, M., O’Neill, P. and Steuten, L., 2020. Realising the Value…
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
…are the most up-to-date and appropriate for estimating the global pull incentive (Brassel et al., 2023). The estimates are based on a review of cost and success estimates for antibiotics…